Literature DB >> 24706057

Levels of hepatitis B virus replicative intermediate in serum samples of chronic hepatitis B patients.

Bhupesh Singla1, Anuradha Chakraborti, Bal Krishan Sharma, Shweta Kapil, Yogesh K Chawla, Sunil K Arora, Ashim Das, Radha K Dhiman, Ajay Duseja.   

Abstract

Hepatitis B virus (HBV) cccDNA levels is an absolute marker of HBV replication in the liver of HBV infected patients. This study aimed to quantify the HBV cccDNA levels in sera and liver tissue samples of treatment naïve patients with chronic hepatitis B. Eighty one chronic hepatitis B (CHB) treatment naïve patients were enrolled from January 2009 to June 2011. Total HBV DNA and HBV cccDNA levels were quantified using sensitive real time PCR assay. The mean age of recruited patients was 34 ± 11.5 years. Fifty four (66.7%) patients were HBeAg negative. Liver tissue samples were available from 2 HBeAg positive and 21 HBeAg negative CHB patients. The amount of total intrahepatic HBV DNA ranged from 0.09 to 1508.92 copies/cell. The median intrahepatic HBV cccDNA was 0.31 and 0.20 copies/cell in HBeAg positive and HBeAg negative cases, respectively. Serum HBV cccDNA was detectable in 85.2 % HBeAg positive and 48.1% HBeAg negative CHB patients. Median serum HBV cccDNA was 46,000 and 26,350 copies/mL in HBeAg positive and HBeAg negative subjects, respectively. There was a significant positive correlation between the levels of intrahepatic total HBV DNA and intrahepatic HBV cccDNA (r = 0.533, p = 0.009). A positive correlation was also seen between serum HBV cccDNA levels and serum HBV DNA levels (r = 0.871, p < 0.001). It was concluded that serum HBV cccDNA could be detectable in higher proportion of HBeAg positive patients compared to HBeAg negative patients. Moreover, the median level of serum HBV cccDNA was significantly higher in HBeAg positive patients in contrast to HBeAg negative subjects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706057     DOI: 10.1007/s11033-014-3339-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  32 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 2.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

3.  Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks.

Authors:  M Lu; G Hilken; D Yang; T Kemper; M Roggendorf
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

Authors:  S R Lewin; R M Ribeiro; T Walters; G K Lau; S Bowden; S Locarnini; A S Perelson
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

5.  Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

Authors:  Pietro Lampertico; Mauro Viganò; Elena Manenti; Massimo Iavarone; Giovanna Lunghi; Massimo Colombo
Journal:  Hepatology       Date:  2005-12       Impact factor: 17.425

6.  Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.

Authors:  Danny Ka-Ho Wong; Wai-Kay Seto; James Fung; Philip Ip; Fung-Yu Huang; Ching-Lung Lai; Man-Fung Yuen
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-01       Impact factor: 11.382

7.  Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B.

Authors:  Jie Shao; Lai Wei; Hao Wang; Yan Sun; Lan-Fang Zhang; Jing Li; Jian-Qiang Dong
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

8.  HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Authors:  Ying Chen; Johnny Sze; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

Review 9.  Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.

Authors:  V T T Nguyen; M G Law; G J Dore
Journal:  J Viral Hepat       Date:  2009-03-17       Impact factor: 3.728

10.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

Authors:  J E Newbold; H Xin; M Tencza; G Sherman; J Dean; S Bowden; S Locarnini
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  3 in total

Review 1.  Detection of HBV Covalently Closed Circular DNA.

Authors:  Xiaoling Li; Jinghua Zhao; Quan Yuan; Ningshao Xia
Journal:  Viruses       Date:  2017-06-06       Impact factor: 5.048

2.  Oral administration of encapsulated bovine lactoferrin protein nanocapsules against intracellular parasite Toxoplasma gondii.

Authors:  Namrata Anand; Rakesh Sehgal; Rupinder Kaur Kanwar; Mohan Lal Dubey; Rakesh Kumar Vasishta; Jagat Rakesh Kanwar
Journal:  Int J Nanomedicine       Date:  2015-10-08

3.  Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B.

Authors:  Zahra Tajik; Hossein Keyvani; Farah Bokharaei-Salim; Mohammad Reza Zolfaghari; Shahin Fakhim; Maryam Keshvari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2015-09-29       Impact factor: 0.660

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.